USPTO Examiner ZOU NIANXIANG - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18779961PREFUSION-STABILIZED HMPV F PROTEINSJuly 2024January 2025Allow610NoNo
18608668ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTIONMarch 2024October 2025Allow1921YesNo
18597598MATERIALS AND METHODS RELATING TO IMMUNOGENIC EPITOPES FROM HUMAN PAPILLOMAVIRUSMarch 2024October 2025Allow1920NoNo
18436426COMPOSITIONS AND METHODS FOR ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF CODING RIBONUCLEIC ACIDSFebruary 2024December 2024Allow1010NoNo
18412674VLP Stabilized Vaccine CompositionsJanuary 2024May 2025Allow1630NoNo
18269284SOLANESOL VACCINE ADJUVANTS AND METHODS OF PREPARING SAMEJanuary 2024November 2024Allow1711NoNo
18483662IMMUNOSTIMULATORY METHODOctober 2023November 2025Allow2511NoNo
18476921MERS-CoV VaccineSeptember 2023October 2025Abandon2510NoNo
18475950Desmoglein 2 (DSG2) Binding Proteins and Uses ThereforSeptember 2023July 2025Allow2210NoNo
18372556COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE MULTI-TARGETED ANTIGENSSeptember 2023January 2025Allow1610NoNo
18461815METHOD FOR QUANTIFYING DNA FRAGMENTS IN A SAMPLE BY SIZESeptember 2023July 2025Allow2310NoNo
18455151RECOMBINANT ADENOVIRUSES AND USES THEREOFAugust 2023January 2025Allow1610YesNo
18236676CANCER IMMUNOTHERAPY USING VIRUS PARTICLESAugust 2023March 2025Allow1921YesNo
18353421Vaccines For Recurrent Respiratory Papillomatosis And Methods Of Using The SameJuly 2023July 2025Allow2430NoNo
18207752METHODS AND COMPOSITIONS FOR TREATING CANCERSJune 2023May 2025Allow2330YesNo
18329696NOVEL VACCINES AGAINST HPV AND HPV-RELATED DISEASESJune 2023September 2024Allow1610NoNo
18328812RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21June 2023May 2025Allow2421NoNo
18323493ANTI-HUMAN PAPILLOMAVIRUS 16 E6 T CELL RECEPTORSMay 2023September 2024Allow1610NoNo
18199044COMPOSITIONS, METHODS AND USES FOR THERMALLY STABLE HUMAN PAPILLOMAVIRUS FORMULATIONSMay 2023November 2024Abandon1810NoNo
18319865IMMUNE COMPLEXMay 2023August 2024Allow1510NoNo
18318325NOVEL VESICULAR STOMATITIS VIRUS AND VIRUS RESCUE SYSTEMMay 2023January 2025Allow2020YesNo
18317616NOVEL ONCOLYTIC VIRUSES FOR SENSITIZING TUMOR CELLS TO KILLING BY NATURAL KILLER CELLSMay 2023January 2025Allow2020NoNo
18142697VACCINE COMPOSITIONSMay 2023October 2025Abandon2930NoNo
18306082SEXUALLY TRANSMITTED DISEASE VACCINESApril 2023November 2024Abandon1910NoNo
18194864COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS THROUGH STIMULATED INNATE IMMUNITY IN COMBINATION WITH ANTIVIRAL COMPOUNDSApril 2023October 2025Abandon3020NoNo
18192352RSV F Protein MutantsMarch 2023March 2025Allow2320NoNo
18021258Vaccine Composition for Preventing Tuberculosis Comprising Chorismate MutaseFebruary 2023January 2026Allow3510NoNo
18158940Compositions and Methods for Promoting Immune Responses to Human Immunodeficiency VirusJanuary 2023August 2024Allow1910YesNo
18151182NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOFJanuary 2023November 2024Allow2220NoNo
18149922CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated DiseaseJanuary 2023March 2025Abandon2721NoNo
18069159HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENTDecember 2022November 2024Abandon2311NoNo
18074302HEPATITIS B VACCINES AND USES OF THE SAMEDecember 2022October 2024Allow2221YesNo
18058619Modified Marek's Disease Virus, and Vaccines Made TherefromNovember 2022January 2025Allow2630NoNo
18057201METHOD FOR SEQUENCING A DIRECT REPEATNovember 2022November 2024Abandon2420NoNo
18053283SYSTEMS AND METHODS TO IMPROVE VACCINE EFFICACYNovember 2022October 2025Abandon3540YesNo
17997886VACCINES AGAINST VIRAL PATHOGENSNovember 2022February 2026Allow4010NoNo
17995722TARGETED DELIVERY OF AN INHIBITOR OF MIR-21 TO MACROPHAGES FOR THE TREATMENT OF PULMONARY FIBROSISOctober 2022January 2026Allow3910NoNo
17822213DETECTION OF SARS-COV-2 USING RNA MULTI-ARM JUNCTION LOGIC GATESAugust 2022December 2025Allow3910NoNo
17904897METHOD FOR DETECTING SINGLE-STRANDED RNA VIRUSAugust 2022March 2026Allow4320YesNo
17794913ONCOLYTIC VIRUS COMPOSITIONS INCLUDING IL-15 COMPLEX AND METHODS FOR THE TREATMENT OF CANCERJuly 2022December 2025Allow4110NoNo
17853783HPV VACCINESJune 2022November 2025Abandon4140NoYes
17835949DNA POLYMERASE, APTAMER, WARM-START DNA POLYMERASE AND PREPARATION METHODS AND APPLICATION THEREOFJune 2022October 2025Allow4010YesNo
17835071THERAPEUTIC MRNA VACCINE FOR MALIGNANCIESJune 2022September 2025Allow3910YesNo
17781826VACCINE CONJUGATESJune 2022December 2025Abandon4210NoNo
17749163Lipid-DNA Labeling of Lipid Bilayer Particles for Amplification QuantitationMay 2022May 2025Allow3610NoNo
17777589HYBRID VIRUS-LIKE PARTICLES AND USE THEREOF AS A THERAPEUTIC HEPATITIS B VACCINEMay 2022September 2025Abandon4010NoNo
17775562BIOMARKERS FOR NANOPARTICLE COMPOSITIONSMay 2022December 2025Abandon4301NoNo
17726431NEUTRALIZING ANTIBODY TESTING AND TREATMENTApril 2022July 2025Abandon3910NoNo
17769839HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOFApril 2022December 2025Abandon4310NoNo
17721134IMMUNE CELLS EXPRESSING RECEPTOR SPECIFIC TO CLASS I MHC MOLECULE AND INTERFERING RNA FOR HLA GENEApril 2022October 2025Abandon4301NoNo
17766015A VIRAL EXPOSURE SIGNATURE FOR DETECTION OF EARLY STAGE HEPATOCELLULAR CARCINOMAApril 2022November 2025Allow4311NoNo
17701270BIOMATERIAL-BASED ANTIGEN FREE VACCINE AND THE USE THEREOFMarch 2022August 2025Allow4110YesNo
17761064MATERIALS AND METHODS FOR DETECTING HUMAN PAPILLOMA VIRUSMarch 2022November 2025Abandon4410NoNo
17639949METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALSMarch 2022October 2025Abandon4410NoNo
17682358RECOMBINANT VACCINE AGAINST MAREK'S DISEASE AND NEWCASTLE DISEASEFebruary 2022November 2024Allow3340YesNo
17670811SARS CoV-2 INFECTIVITY DETERMINATION ASSAYFebruary 2022December 2025Abandon4711NoNo
17590353ASSAY FOR NEUTRALIZING ANTIBODY TESTING AND TREATMENTFebruary 2022June 2025Abandon4010NoNo
17578312VACCINE COMBINATION AND METHOD FOR USING THE SAMEJanuary 2022August 2025Allow4320NoNo
17563787METHODS FOR TREATING CANCER WITH ACTIVATING ANTIGEN CARRIERSDecember 2021August 2025Abandon4440YesNo
17596847An Aptamer for Dengue Virus and Related Methods and ProductsDecember 2021August 2025Allow4411YesNo
17621033IMPROVED THERAPEUTIC COMPOSITION COMPRISING HEPATITIS B ANTIGEN HAVING S, PRE-S1 AND PRE-S2 PROTEIN, ALUMINIUM PHOSPHATE AND INTERFERON-ALPHA AND USE THEREOF FOR TREATMENT OF HEPATITIS BDecember 2021June 2025Abandon4210NoNo
17300929Assay For Neutralizing Antibody Testing And TreatmentDecember 2021June 2025Abandon4210NoNo
17596547Hepatitis B Virus (HBV) Vaccines and Uses ThereofDecember 2021July 2025Abandon4310NoNo
17596366COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PD-L1 INHIBITORSDecember 2021June 2025Abandon4310NoNo
17617209MEDICINAL COMPOSITIONDecember 2021August 2025Abandon4411NoNo
17614064VIRAL VECTORNovember 2021February 2025Allow3911NoNo
17529206CROSS PRIMER ISOTHERMAL AMPLIFICATION PRIMER SET FOR DETECTING TOBACCO RINGSPOT VIRUS, KIT AND APPLICATION THEREOFNovember 2021May 2025Abandon4210NoNo
17610592COMPOSITIONS AND METHODS FOR TREATING T CELL EXHAUSTIONNovember 2021March 2025Allow4041YesNo
17595119ATTENUATED IBV WITH EXTENDED CELL CULTURE AND TISSUE TROPISMNovember 2021May 2025Allow4220YesNo
17607573INTRINSIC SYSTEM FOR VIRAL VECTOR TRANSGENE REGULATIONOctober 2021July 2025Allow4411NoNo
17507496Novel Method for Obtaining Efficient Viral Vector-Based Compositions for Vaccination or Gene TherapyOctober 2021January 2025Allow3941NoNo
17594494Methods for Inducing a Safe Immune Response Against Polio VirusOctober 2021May 2025Abandon4310NoNo
17603789PHAGE TEST KITOctober 2021May 2025Abandon4330NoNo
17603125USE OF PROBES TO DETECT TOXINOGENIC CYANOBACTERIA, DETECTION METHOD AND CORRESPONDING KITSOctober 2021August 2025Allow4620YesNo
17602988ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING A MEMBER OF THE B7 FAMILY OF COSTIMULATORY LIGANDS AND ADAOctober 2021March 2025Abandon4110NoNo
17601557TREATMENT FOR RESTORING UREAGENESIS IN CARBAMOYL PHOSPHATE SYNTHETASE 1 DEFICIENCYOctober 2021December 2024Allow3810NoNo
17493647FUCOSYLLACTOSE AS BREAST MILK IDENTICAL NON-DIGESTIBLE OLIGOSACCHARIDE WITH NEW FUNCTIONAL BENEFITOctober 2021November 2024Abandon3740NoNo
17600588HUMAN VACCINE COMPOSITIONS AND METHODS FOR TREATING LEUKEMIASeptember 2021June 2025Allow4510YesNo
17598659AD7-VECTORED VACCINE FOR PREVENTING SARS- COV-2 INFECTIONSeptember 2021March 2025Abandon4110NoNo
17598178IMMUNOASSAY METHOD AND DETECTION KIT FOR RESPIRATORY TRACT VIRUSSeptember 2021March 2025Abandon4101NoNo
17474240Heterologous Prime Boost VaccineSeptember 2021August 2025Abandon4711NoNo
17438050KIT FOR EARLY SCREENING OF LIVER CELL CANCER AND PREPARATION METHOD AND USE THEREOFSeptember 2021April 2025Allow4420YesNo
17471709Method for rescuing influenza virus and composition thereforSeptember 2021February 2025Abandon4110NoNo
17470283METHOD FOR DETERMINING IMMUNE COMPETENCE AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2September 2021August 2025Allow4720YesNo
17437266CORONAVIRUS VACCINES AND USES THEREOFSeptember 2021January 2025Abandon4010NoNo
17436183HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONSSeptember 2021February 2025Abandon4210NoNo
17463618SYSTEM AND METHOD FOR DIGITAL REMOTE PRIMARY, SECONDARY, AND TERTIARY COLOR CALIBRATION VIA SMART DEVICE IN ANALYSIS OF MEDICAL TEST RESULTSSeptember 2021May 2025Abandon4510NoNo
17463824BIOMARKERS AND USES THEREOF IN THE TREATMENT OF CHRONIC HBV INFECTIONSeptember 2021January 2025Abandon4101NoNo
17404105GENERATING HPV ANTIGEN-SPECIFIC T CELLS FROM A NAÏVE T CELL POPULATIONAugust 2021July 2025Allow4721NoNo
17424499Personalized Immunotherapy for Rejuvenating, Activating and Strengthening Exhausted and Dysfunctional T Cells, Reducing PD-1, and Improving Immune FunctionJuly 2021June 2025Allow4711NoNo
17421346LIGHT-RESPONSIVE POLYPEPTIDES AND METHODS OF USE THEREOFJuly 2021December 2024Allow4120NoNo
17361462COMBINATION PRODUCT FOR USE IN TUMOR VACCINATIONJune 2021March 2025Abandon4501NoNo
16759591VIRUS-LIKE PARTICLES WHICH CAN BE USED IN THE TREATMENT OF ALLERGIESJune 2021June 2025Allow6011NoNo
17311480A METHOD FOR PROVIDING A VLPJune 2021December 2024Abandon4201NoNo
17295384Therapy for Treating Cancer with an Intratumoral or Intravenous Administration of a Recombinant MVA Encoding 4-1BBL (CD137L) and/or CD40LMay 2021June 2025Allow4911NoNo
17287497MUTANT VACCINIA VIRUSES AND USE THEREOFApril 2021November 2024Abandon4201NoNo
17309038METHODS AND COMPOSITIONS FOR TREATING NEGATIVE-SENSE SINGLE-STRANDED RNA VIRUSApril 2021October 2024Allow4211YesNo
17284087PD-L1 PRESENTING PLATELETS REVERSE NEW-ONSET TYPE 1 DIABETESApril 2021February 2025Abandon4720NoNo
17221032COMPOSITIONS AND METHODS FOR TREATING VULVAR DYSPLASIAApril 2021October 2023Abandon3051NoNo
17141885METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TESTJanuary 2021February 2025Allow4951YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZOU, NIANXIANG.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.5%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
7
Allowed After Appeal Filing
3
(42.9%)
Not Allowed After Appeal Filing
4
(57.1%)
Filing Benefit Percentile
70.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ZOU, NIANXIANG - Prosecution Strategy Guide

Executive Summary

Examiner ZOU, NIANXIANG works in Art Unit 1671 and has examined 92 patent applications in our dataset. With an allowance rate of 70.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 42 months.

Allowance Patterns

Examiner ZOU, NIANXIANG's allowance rate of 70.7% places them in the 33% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by ZOU, NIANXIANG receive 2.57 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ZOU, NIANXIANG is 42 months. This places the examiner in the 18% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +32.6% benefit to allowance rate for applications examined by ZOU, NIANXIANG. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.2% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 36.4% of cases where such amendments are filed. This entry rate is in the 55% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 85.7% of appeals filed. This is in the 79% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 69.2% are granted (fully or in part). This grant rate is in the 76% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.3% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.